Vertex and crispr therapeutics present new data on more patients with longer follow-up treated with exagamglogene autotemcel (exa-cel) at the 2022 european hematology association (eha) congress

Boston & zug, switzerland & cambridge, mass.--(business wire)--vertex pharmaceuticals incorporated (nasdaq: vrtx) and crispr therapeutics (nasdaq: crsp) announce presentation of new data on exa-cel, formerly known as ctx001™, from climb-111, climb-121 and climb-131 highlighting the potentially transformative profile of this investigational therapy for people with transfusion-dependent beta thalassemia (tdt) or severe sickle cell disease (scd) and provided additional program updates. new data fo
VRTX Ratings Summary
VRTX Quant Ranking